H.C. Wainwright raised its price target for Codexis (NASDAQ:CDXS) to $22.50 from $16.50 and reiterated its “buy” rating, saying food and next-generation sequencing products, along with new therapeutic candidates, are...

Analysts at SVB Leerink and H.C. Wainwright downgraded Immunogen (NASDAQ:IMGN) and lowered their price targets after the company’s FORWARD-I Phase 3 trial with mirvetuximab soravtansine did not meet its primary endpoint...

SVB Leerink initiated coverage of MannKind (NASDAQ:MNKD) with an “outperform” rating and a 12-month price target of $3. The stock closed at $1.77 on March 1. Analyst Dr. Pasha Sarraf writes that his rating is based on...

AGP/Alliance Global Partners launched coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and price target of $2.30. The stock closed at $1.48 on March 1. “OpGen’s approach to antibiotic resistance identification...

H.C. Wainwright launched coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $27 price target. The stock closed at $26.80 on Feb. 27. Albireo is focused on rare pediatric and adult cholestatic diseases...

Dawson James Securities initiated coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and price target of $7. The stock closed at $4.20 on Feb. 26. The focus at Caladrius is cell therapy, with an...

Corindus Vascular Robotics (NYSE American:CVRS) privately sold 10,872,716 of its common shares at a price of $1.3796 each to a large institutional investor for gross proceeds of about $15-million. Net proceeds of about...

H.C. Wainwright launched coverage of Pulse Biosciences (NASDAQ:PLSE) with a “buy” rating and price target of $27. The stock closed at $18.23 on Feb. 22. Analyst Swayampakula Ramakanth writes that his recommendation is...

Stifel upgraded Obalon Therapeutics (NASDAQ:OBLN) to “buy” from “hold” and raised its price target to $3 from $2.50, saying the company is entering 2019 with “multiple incremental/critical adoption drivers now in...

H.C. Wainwright launched coverage of BioTime (NYSE American:BTX) with a “buy” rating and $4 price target. The stock closed at $1.15 on Feb. 20. Analyst Joseph Pantginis writes that BioTime was originally focused on...

Roth Capital Partners launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $14 price target. The stock closed at $4.84 on Feb. 19. “Arcturus is a hidden gem in a sea of RNA medicines...

H.C. Wainwright initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $36 price target. The stock closed at $24.03 on Feb. 19. Analyst Debjit Chattopadhyay writes that Homology’s platform...

Roth Capital Partners initiated coverage of Chiasma (NASDAQ:CHMA) with a “buy” rating and $16 price target. The stock closed at $3.87 on Feb. 15. “With two Phase 3 readouts on the horizon, Chiasma is a fallen angel...

BTIG launched coverage of Synlogic (NASDAQ:SYBX) with a “buy” rating and $22 price target. The stock closed at $9.56 on Feb. 12. “We view Synlogic’s approach to correct inborn errors of metabolism via addition of key...

BTIG launched coverage of Geron (NASDAQ:GERN) with a “buy” rating and $4 price target. The stock closed at $1.31 on Feb. 12. Geron is focused on development of imetelstat, a telomerase inhibitor active in the treatment...

H.C. Wainwright initiated coverage of France-based Inventiva (PSE:IVA) with a “buy” rating and price target of €19. The stock closed at €6.40 on Feb. 12. Inventiva was spun out of Abbott Labs in 2012 and is focused on...

BTIG initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and price target of $5.50. The stock closed at $2.96 on Feb. 12. “MEI Pharma is developing in-licensed drugs that we see as having good chances of...